Drug Designing: Open Access
Open Access

5-methoxytryptophan (5-MTP) is a new class of tryptophan metabolites with anti-cancer and antisepsis actions

9^th Annual Congress on Drug Design & Drug Formulation

October 19-20, 2017 Seoul, South Korea

Kenneth K Wu

National Tsing Hua University, Taiwan

Posters & Accepted Abstracts: Drug Des

Abstract :

We reported the discovery of 5-MTP as a novel endogenous tryptophan metabolite with anti-cancer and anti-inflammatory actions. 5-MTP is produced by human fibroblasts and endothelial cells via two enzymatic steps and released into extracellular milieu. It blocks cancer cell COX-2 overexpression and inhibits cancer cell migration and cancer growth and metastasis in a xenograft model. Endothelium-derived 5-MTP protects endothelial barrier function and inhibits LPS-and cytokine-induced release of cytokines and chemokines from macrophages. 5-MTP is effective in controlling cytokine storm, reducing organ damage and increasing survival in murine sepsis models. 5-MTP is detected in human blood: Mean serum 5-MTP concentration of 30 healthy subjects is 1.02 �?¼M. Serum 5-MTP level is reduced in patients with sepsis. These finding indicate that 5-MTP is a valuable lead compound for developing new anti-sepsis and anti-cancer therapeutic agents and serum 5-MTP may serve as a theranostic biomarker for selecting patients for 5-MTP therapy.